My research group focuses on identifying mechanisms that limit the sensitivity to targeted therapy in solid tumors, in particular to PI3K/Akt/mTOR inhibitors and anti-HER2 agents. By investigating how cancer cells escape the therapeutic pressure of these drugs, we can better identify patients who are more likely to respond to a specific therapy and increase effectiveness of such therapies by testing novel combinations. Concomitantly, we analyze biopsies obtained from patients who were treated with the same compounds as the ones we study in the laboratory. This is necessary in order to validate our preclinical findings and to uncover new (and targetable) possible genomic aberrations acquired by cancer cells during therapeutic stress and selection. Our final aim is to provide insights into designing more-effective clinical trials that test novel therapeutic combinations in precise subsets of cancer patient populations.
José Baselga, MD, PhD
Physician-in-Chief, Memorial Hospital
Research FocusMemorial Sloan Kettering Physician-in-Chief José Baselga studies mechanisms of resistance to targeted therapies and identification of novel therapeutic combinations in solid cancers.
EducationMD, PhD, Universitat Autonoma de Barcelona (Spain)
- Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science. 2017 Mar 24;355(6331):1324-30.
- Juric D, Castel P, Griffit M, Griffith OL, Won HH, Ellis H, Ebbesen S, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, Baselga J*, Scaltriti M. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor. Nature. 2015. DOI: 10.1038/nature13948. PMC In-Progress. *Corresponding author.